Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1414-1419

  Suemori, Koichiro ^a   Fujiwara, Hiroshi ^a   Ochi, Toshiki ^a   Azuma, Taichi ^a   Yamanouchi, Jun ^a   Narumi, Hiroshi ^a   Yakushijin, Yoshihiro ^a   Hato, Takaaki ^a   Hasegawa, Hitoshi ^a   Yasukawa, Masaki ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC MYELOID LEUKEMIA ANTIGEN 66; EPITOPE; HLA A24 ANTIGEN; LEUKEMIA ANTIGEN; MESSENGER RNA; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BLOOD ANALYSIS; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, CD34; ANTIGENS, NEOPLASM; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; LEUKEMIA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 44449130114     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00823.x     Document Type: Article

References (20)

1. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
2. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature 2001; 411: 380-4.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-15.
4. Yang XF, Wu CJ, McLaughlin S et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA 2001; 98: 7492-7.
5. Wu CJ, Biernacki M, Kutok JL et al. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res 2005; 11: 4504-11.
6. + T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98: 1872-81.
7. Karaki S, Kariyone A, Kato N, Kano K, Iwakura Y, Takiguchi M. HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies. Immunogenetics 1993; 37: 139-42.
8. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163-75.
9. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-19.
10. Tsuboi A, Oka Y, Udaka K et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51: 614-20.
11. Gomez-Nunez M, Pinilla-Ibarz J, Dao T et al. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res 2006; 30: 1293-8.
12. + cytotoxic T-lymphocyte specific for WT1 peptide. Blood 2000; 95: 286-93.
13. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A-24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001; 97: 2903-7.
14. + human cytotoxic T cell clones directed against herpes simplex virus. J Immunol 1988; 140: 3419-25.
15. Azuma T, Otsuki T, Kuzushima K, Froelich CJ, Fujita S, Yasukawa M. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2004; 10: 7402-12.
16. Koenig JJ, Teubel W, Romijn JC, Schroeder FH, Hagemeijer A. Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum Pathol 1996; 27: 720-7.
17. Chang GT, Tapsi N, Steenbeek M et al. Identification of a gene on human chromosome 8q11 that is differentially expressed during prostate-cancer progression. Int J Cancer 1999; 83: 506-11.
18. Michor F, Hughes TP, Iwasa Y et al. Dynamics of chronic myeloid leukemia. Nature 2005; 435: 1267-70.
19. Gabbianelli M, Boccoli G, Cianetti L, Russo G, Testa U, Peschle C. HLA expression in hematopoietic development. Class I and II antigens are induced in the definitive erythroid lineage and differentially modulated by fetal liver cytokines. J Immunol 1990; 144: 3354-60.
20. Yan Y, Phan L, Yang F et al. A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J Immunol 2004; 172: 651-60.